BioCentury
ARTICLE | Clinical News

ABI-H0731: Ph I started

November 10, 2016 11:22 PM UTC

Assembly began a single-blind, placebo-controlled, New Zealand Phase I trial of oral ABI-H0731 in about 114 subjects. The first part will evaluate multiple doses of oral ABI-H0731 for 1, 7 or 28 days ...

BCIQ Company Profiles

Assembly Biosciences Inc.

BCIQ Target Profiles

HBV core protein